Table 2 Expression of HDAC1, H3Ac and H4Ac and clinicopathological characteristics in breast invasive ductal carcinoma patients

Breast invasive ductal carcinoma

100(100%)

67(67%)

33(33%)

90(90%)

10(10%)

79(79%)

21(21%)

0.243*

Control

22(100%)

3 (14%)

19(86%)

< 0.001

14(64%)

8 (36%)

0.004*

20(91%)

2 (9%)

Age (year)

≤ 40

20(20%)

8(40%)

12(60%)

0.004

18(90%)

2(10%)

1.000*

17(85%)

3(15%)

0.554*

> 40

80(80%)

59(74%)

21(26%)

72(90%)

8(10%)

62(78%)

18(22%)

Tumour size(cm)

≤ 5

91(91%)

62(68%)

29(22%)

0.472*

84(92%)

7(8%)

0.044*

74(81%)

17(19%)

0.089*

> 5

9 (9%)

5(56%)

4(44%)

6(67%)

3(23%)

5(56%)

4(44%)

Differentiation

well

25(25%)

8(32%)

17(68%)

< 0.001

24(96%)

1(4%)

0.444*

20(80%)

5(20%)

0.887

poor

75(75%)

59(79%)

16(21%)

66(88%)

9(12%)

59(79%)

16(21%)

Clinical stage

I

20(20%)

12(60%)

8(40%)

0.007

17(85%)

3(15%)

0.034*

18(90%)

2(10%)

0.227

II

46(46%)

38(83%)

8(17%)

45(98%)

1(2%)

37(80%)

9(20%)

III-IV

34(34%)

17(50%)

17(50%)

28(82%)

6(18%)

24(71%)

10(29%)

Lymph node metastasis

Positive

48(48%)

40(83%)

8(17%)

0.001

43(90%)

5(10%)

1.000*

37(77%)

11(23%)

0.651

Negative

52(52%)

27(52%)

25(48%)

47(90%)

5(10%)

42(81%)

10(19%)